The generation and matrix stabilization of ligand-free, small platinum nanoclusters (NCs) Pt is presented. The metal-organic framework-template approach is based on encapsulating CO-ligated, atom-precise Pt Chini clusters [{Pt(CO)}] into the zeolitic imidazolate framework ZIF-8. The selective formation of the air-stable inclusion compound [NBu][{Pt(CO)}]@ZIF-8 of defined atomicity Pt and with Pt loadings of 1-20 wt % was monitored by UV/vis and IR spectroscopy and was confirmed by high-resolution transmission electron microscopy (HR-TEM), high-angle annular dark-field scanning transmission electron microscopy (HAADF-STEM), X-ray photoelectron spectroscopy (XPS), and powder X-ray diffraction (PXRD). Thermally induced decarbonylation at 200 °C yields the composite material Pt@ZIF-8 with a cluster atomicity close to 12, irrespective of the Pt loading. The PtNCs retain their size even during annealing at 300 °C for 24 h and during catalytic hydrogenation of 1-hexene at 25 °C in the liquid phase. The Pt@ZIF-8 material can conveniently be used for storing small PtNCs and their further processing. Removal of the protective ZIF-8 matrix under acidic conditions and transfer of the PtNCs to carbon substrates yields defined aggregation to small Pt nanoparticles (1.14 ± 0.35 nm, HR-TEM), which have previously shown exceptional performance in the electrocatalytic oxygen reduction reaction (ORR).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jacs.9b07083 | DOI Listing |
Cureus
December 2024
Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, Cracow, POL.
Gastric cancer is a common type of gastrointestinal tract malignancy. It is characterized by a poor prognosis - median survival for metastatic disease is about 12 months. A small percentage of gastric cancer is characterized by high sensitivity to systemic treatment, resulting in deep and durable responses.
View Article and Find Full Text PDFCancer Manag Res
January 2025
Department of Respiratory and Critical Care Medicine, Fuyang People's Hospital, Fuyang, 236000, People's Republic of China.
Objective: This study aims to assess the clinical significance of the peripheral blood neutrophil-to-lymphocyte ratio (NLR) in predicting chemotherapy outcomes for patients with small cell lung cancer (SCLC).
Methods: A cohort of 44 patients diagnosed with SCLC between January 2021 to June 2022 at Fuyang People's Hospital was selected for analysis. All patients in this group received a first-line platinum-based doublet chemotherapy regimen.
Small
January 2025
School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Widely used catalysts for electrocatalytic hydrogen (H) evolution reaction (HER) have high platinum (Pt) contents and show low efficiencies in neutral and alkaline solutions. Herein, a carbon nanotube (CNT) supported Pt catalyst (Pt/CNT45) with 1 wt.% Pt is fabricated.
View Article and Find Full Text PDFJ Chin Med Assoc
January 2025
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.
Background: Limited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment options for this distinct subtype. The present study explored the clinical features and outcomes of HER2-mutant NSCLC in a real-world setting.
Methods: Relevant data were collected from patients with advanced or recurrent HER2-mutant NSCLC who received systemic therapy between 2011 and 2021 and were followed up until 2022 at two medical centers in Taiwan.
Clin Lung Cancer
January 2025
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Although chemoimmunotherapy is recommended for advanced nonsquamous non-small cell lung cancer (NSCLC) with low programmed cell death ligand 1 (PD-L1) expression, no head-to-head comparisons of immune checkpoint inhibitors (ICIs) have been performed. Therefore, we compared the effect and safety of regimens in these patients to guide evidence-based treatment.
Methods: This retrospective study included patients with advanced nonsquamous NSCLC with a PD-L1 tumor proportion score of 1% to 49% administered ICI combination platinum-based chemotherapy between May 2018 and May 2023 at 19 institutions in Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!